Kodiak’s KSI-301 Has Narrower Path Forward After Phase II/III Failure In Wet AMD
Monthly dosing remains a possibility in wet age-related macular degeneration, though diabetic macular edema and retinal vein occlusion look more promising.
You may also be interested in...
Phase II Data May Be Good Sign For 8mg Aflibercept, But Will Payers Bite?
There are concerns that even with better efficacy and dosing versus Eylea and biosimilars, payers may impose step-edits on Regeneron’s new high-dose version.
Roche Has Eylea In Its Sights After Farcimab Approval
Roche’s bispecific antibody, to be called Vabysmo, has got US approval for wet age-related macular degeneration and diabetic macular edema, markets where Bayer and Regeneron's Eylea is a huge seller. The Swiss company hopes that its less-frequent dosing advantage and a price that offers savings over time will make an impact on the market.
Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data
The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.